MolMed NGR-hTNF four studies accepted for presentation at ASCO 2013

Top Quote MolMed NGR-hTNF clinical development update, four studies accepted for presentation at ASCO 2013. End Quote
  • (1888PressRelease) May 21, 2013 - MolMed S.p.A. (MLM.MI) today announced that four studies on its investigational therapeutics NGR-hTNF and TK have been accepted for presentation at the 49th ASCO Annual Meeting, that will take place in Chicago (IL, USA) from May 31st to June 4th, 2013. Abstracts are now available on the ASCO 2013 website (

    This year yet again MolMed had an important number of studies accepted for presentation at ASCO meeting, confirming the quality of our clinical development programme.

    We are particularly pleased to communicate that the study on our cell therapy TK has been selected for an oral presentation in the section "Leukemia, Myelodysplasia, and Transplantation", reflecting the recognised potential of our strategy. In particular, results from an overall assessment on 128 patients with high-risk haematological malignancies who were treated with TK cells in 10 completed Phase I/II clinical trials in different countries will be presented. Long-term follow-up data confirm the clinical benefit and the safety of this cell therapy.

    For NGR-hTNF, new data presented at ASCO will be mainly focused on the results of two randomised Phase II trials: in non-small cell lung cancer (NSCLC) and in soft tissue sarcoma (STS). Both these studies confirm the clinical benefit induced by the treatment, with a very favourable tolerability profile.

    New data disclosed at ASCO will be announced in separate press releases during the meeting.

    This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14 May 1999, as subsequently amended.

    About MolMed
    MolMed S.p.A. is a biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed's pipeline includes two antitumour therapeutics in clinical development: TK, a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression, in Phase III in high-risk acute leukaemia; NGR-hTNF, a novel vascular targeting agent, in Phase III in malignant pleural mesothelioma and in Phase II in six more indications: colorectal, lung (small-cell and non-small-cell), liver and ovarian cancer, and soft tissue sarcomas. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP production of clinical-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy. The Company's shares are listed on the main market (MTA) of the Milan Stock Exchange. (Ticker Reuters: MLMD.MI)

    Fonte: MolMed

  • FB Icon Twitter Icon In-Icon
Contact Information